Literature DB >> 30683985

The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD).

Zahra Safari1,2, Philippe Gérard3.   

Abstract

NAFLD is currently the main cause of chronic liver disease in developed countries, and the number of NAFLD patients is growing worldwide. NAFLD often has similar symptoms to other metabolic disorders, including type 2 diabetes and obesity. Recently, the role of the gut microbiota in the pathophysiology of many diseases has been revealed. Regarding NAFLD, experiments using gut microbiota transplants to germ-free animal models showed that fatty liver disease development is determined by gut bacteria. Moreover, the perturbation of the composition of the gut microbiota has been observed in patients suffering from NAFLD. Numerous mechanisms relating the gut microbiome to NAFLD have been proposed, including the dysbiosis-induced dysregulation of gut endothelial barrier function that allows for the translocation of bacterial components and leads to hepatic inflammation. In addition, the various metabolites produced by the gut microbiota may impact the liver and thus modulate NAFLD susceptibility. Therefore, the manipulation of the gut microbiome by probiotics, prebiotics or synbiotics was shown to improve liver phenotype in NAFLD patients as well as in rodent models. Hence, further knowledge about the interactions among dysbiosis, environmental factors, and diet and their impacts on the gut-liver axis can improve the treatment of this life-threatening liver disease and its related disorders.

Entities:  

Keywords:  Antibiotics; Bile acids; Dysbiosis; Germ-free animals; Gut microbiota; Intestinal permeability; Metabolic syndrome; Non-alcoholic fatty liver disease; Prebiotics; Probiotics

Mesh:

Substances:

Year:  2019        PMID: 30683985     DOI: 10.1007/s00018-019-03011-w

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.207


  155 in total

Review 1.  Prebiotics and lipid metabolism.

Authors:  Nathalie M Delzenne; Christine M Williams
Journal:  Curr Opin Lipidol       Date:  2002-02       Impact factor: 4.776

Review 2.  Effects of fructans-type prebiotics on lipid metabolism.

Authors:  N M Delzenne; N Kok
Journal:  Am J Clin Nutr       Date:  2001-02       Impact factor: 7.045

3.  The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis.

Authors:  A J Wigg; I C Roberts-Thomson; R B Dymock; P J McCarthy; R H Grose; A G Cummins
Journal:  Gut       Date:  2001-02       Impact factor: 23.059

4.  Dietary oligofructose lessens hepatic steatosis, but does not prevent hypertriglyceridemia in obese zucker rats.

Authors:  C A Daubioul; H S Taper; L D De Wispelaere; N M Delzenne
Journal:  J Nutr       Date:  2000-05       Impact factor: 4.798

5.  Long-Term treatment with cisapride and antibiotics in liver cirrhosis: effect on small intestinal motility, bacterial overgrowth, and liver function.

Authors:  A M Madrid; C Hurtado; M Venegas; F Cumsille; C Defilippi
Journal:  Am J Gastroenterol       Date:  2001-04       Impact factor: 10.864

6.  Increased gastrointestinal ethanol production in obese mice: implications for fatty liver disease pathogenesis.

Authors:  K Cope; T Risby; A M Diehl
Journal:  Gastroenterology       Date:  2000-11       Impact factor: 22.682

7.  The gut microbiota as an environmental factor that regulates fat storage.

Authors:  Fredrik Bäckhed; Hao Ding; Ting Wang; Lora V Hooper; Gou Young Koh; Andras Nagy; Clay F Semenkovich; Jeffrey I Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-25       Impact factor: 11.205

8.  Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity.

Authors:  Jeffrey D Browning; Lidia S Szczepaniak; Robert Dobbins; Pamela Nuremberg; Jay D Horton; Jonathan C Cohen; Scott M Grundy; Helen H Hobbs
Journal:  Hepatology       Date:  2004-12       Impact factor: 17.425

9.  Choline deficiency-induced liver damage is reversible in Pemt(-/-) mice.

Authors:  Kristin A Waite; Nora R Cabilio; Dennis E Vance
Journal:  J Nutr       Date:  2002-01       Impact factor: 4.798

10.  Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease.

Authors:  Zhiping Li; Shiqi Yang; Huizhi Lin; Jiawen Huang; Paul A Watkins; Ann B Moser; Claudio Desimone; Xiao-yu Song; Anna Mae Diehl
Journal:  Hepatology       Date:  2003-02       Impact factor: 17.425

View more
  87 in total

Review 1.  Emerging computational tools and models for studying gut microbiota composition and function.

Authors:  Seo-Young Park; Arinzechukwu Ufondu; Kyongbum Lee; Arul Jayaraman
Journal:  Curr Opin Biotechnol       Date:  2020-11-25       Impact factor: 9.740

Review 2.  Non-Alcoholic Fatty Liver Disease and Cardiovascular Comorbidities: Pathophysiological Links, Diagnosis, and Therapeutic Management.

Authors:  Alexandra Jichitu; Simona Bungau; Ana Maria Alexandra Stanescu; Cosmin Mihai Vesa; Mirela Marioara Toma; Cristiana Bustea; Stela Iurciuc; Marius Rus; Nicolae Bacalbasa; Camelia Cristina Diaconu
Journal:  Diagnostics (Basel)       Date:  2021-04-12

Review 3.  Short chain fatty acids and methylamines produced by gut microbiota as mediators and markers in the circulatory system.

Authors:  Maksymilian Onyszkiewicz; Kinga Jaworska; Marcin Ufnal
Journal:  Exp Biol Med (Maywood)       Date:  2020-01-16

Review 4.  Contribution of the Intestinal Microbiome and Gut Barrier to Hepatic Disorders.

Authors:  Daniel M Chopyk; Arash Grakoui
Journal:  Gastroenterology       Date:  2020-06-20       Impact factor: 22.682

Review 5.  NASH and the Gut Microbiome: Implications for New Therapies.

Authors:  Cynthia J Tsay; Joseph K Lim
Journal:  Clin Liver Dis (Hoboken)       Date:  2022-01-28

6.  Lower gut microbiome diversity and higher abundance of proinflammatory genus Collinsella are associated with biopsy-proven nonalcoholic steatohepatitis.

Authors:  Stuart Astbury; Edmond Atallah; Amrita Vijay; Guruprasad P Aithal; Jane I Grove; Ana M Valdes
Journal:  Gut Microbes       Date:  2019-11-07

7.  The Anti-fibrotic Effects of Heat-Killed Akkermansia muciniphila MucT on Liver Fibrosis Markers and Activation of Hepatic Stellate Cells.

Authors:  Shahrbanoo Keshavarz Azizi Raftar; Sara Abdollahiyan; Masoumeh Azimirad; Abbas Yadegar; Farzam Vaziri; Arfa Moshiri; Seyed Davar Siadat; Mohammad Reza Zali
Journal:  Probiotics Antimicrob Proteins       Date:  2021-01-12       Impact factor: 4.609

Review 8.  Dietary carbohydrates and fats in nonalcoholic fatty liver disease.

Authors:  Hannele Yki-Järvinen; Panu K Luukkonen; Leanne Hodson; J Bernadette Moore
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-07-13       Impact factor: 46.802

Review 9.  Lean NAFLD: an underrecognized and challenging disorder in medicine.

Authors:  Sheila Maier; Amanda Wieland; Melanie Cree-Green; Kristen Nadeau; Shelby Sullivan; Miguel A Lanaspa; Richard J Johnson; Thomas Jensen
Journal:  Rev Endocr Metab Disord       Date:  2021-01-03       Impact factor: 6.514

10.  Prolyl Endopeptidase Gene Disruption Improves Gut Dysbiosis and Non-alcoholic Fatty Liver Disease in Mice Induced by a High-Fat Diet.

Authors:  Daixi Jiang; Jianbin Zhang; Shuangzhe Lin; Yuqin Wang; Yuanwen Chen; Jiangao Fan
Journal:  Front Cell Dev Biol       Date:  2021-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.